Kinnate Biopharma Past Earnings Performance

Past criteria checks 0/6

Kinnate Biopharma's earnings have been declining at an average annual rate of -40.2%, while the Biotechs industry saw earnings growing at 17.7% annually.

Key information

-40.2%

Earnings growth rate

7.6%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-73.7%
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Kinnate Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

MUN:6KB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-12730103
30 Jun 230-12731102
31 Mar 230-1223195
31 Dec 220-1163088
30 Sep 220-1113082
30 Jun 220-1052878
31 Mar 220-992674
31 Dec 210-902367
30 Sep 210-771860
30 Jun 210-631449
31 Mar 210-491139
31 Dec 200-36729
30 Sep 200-26620
31 Dec 190-1039

Quality Earnings: 6KB is currently unprofitable.

Growing Profit Margin: 6KB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6KB is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.

Accelerating Growth: Unable to compare 6KB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6KB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).


Return on Equity

High ROE: 6KB has a negative Return on Equity (-73.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.